Our efforts to bring about new innovations
for medical technology still continue today.
SLS Bio Co., Ltd., after its establishment in 2007, secured a professional technical workforce and actively invested in research development to eventually be listed in KONEX in June of 2016, and we are now preparing to be a listed company in KOSDAQ.
Through research and development, the company has already commercialized Fragile X and STR kits, while looking to commercialize products such as rapid allergy diagnostic kits, rapid diagnostic kits for pregnancy, and integrated Bio-Nano technology such as NTMD(Nano Technology Multiplex Diagnosis) in the future. We are also planning to expand our investments in related companies involved in development for new drugs and businesses involved in veterinary regenerative medicine based on stem cells.
In addition, we are accomplishing continuous growth in customer satisfaction and quality of service in relation to our original quality control business for pharmaceutical products and our efficacy evaluation that was established in 2018 for new drugs.
SLS Bio Co., Ltd. will continue to contribute to the improvement of human health through continuous investment in research and development for new and innovative fields, while working to position ourselves as an ethical testing organization that is accurate and trustworthy in quality control for pharmaceuticals and efficacy evaluation for new drugs. We ask for your continued interest and encouragement